Population pharmacokinetics of mavacoxib in osteoarthritic dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 34, Issue 1, 2011, Pages 1-11

  Cox, S R ^a   Liao, S ^b   Payne Johnson, M ^a   Zielinski, R J ^a   Stegemann, M R ^c  

^a PFIZER INC   (United States)

^b Pharmax Research Inc   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARPROFEN; MAVACOXIB;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; BREED; DOG DISEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GROUPS BY AGE; MALE; MULTICENTER STUDY; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; MALE; MODELS, BIOLOGICAL; OSTEOARTHRITIS; PYRAZOLES;

BANANA STREAK VIRUS; CANIS FAMILIARIS;

EID: 78651242899     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2010.01183.x     Document Type: Article

References (20)

1. Anderson, B.J. & Holford, N.H. (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annual Review of Pharmacology and Toxicology, 48, 303-332.
2. Benedetti, M.S., Whomsley, R. & Canning, M. (2007) Drug metabolism in the paediatric population and in the elderly. Drug Discovery Today, 12, 599-610.
3. Benet, L.Z. & Hoener, B.A. (2002) Changes in plasma protein binding have little clinical relevance. Clinical Pharmacology and Therapeutics, 71, 115-121.
4. Bergstrand, M., Plan, E., Kjellsson, M. & Karlsson, M. (2007) A comparison of methods for handling of data below the limit of quantification in NONMEM. Abstr. 1201, p. 16. Available at: Accessed 19 March 2010.
5. Bonate, P. (2006) Pharmacokinetic-Pharmacodynamic Modeling and Simulation. Springer Science+Business Median, Inc., New York.
6. Cox, S.R., Lesman, S.P., Boucher, J.F., Krautmann, M.J., Hummel, B.D., Michels, G., Marsh, S., Fielder, A. & Stegemann, M.R. (2010) The pharmacokinetics of mavacoxib, a long-acting Cox-2 inhibitor, in young adult laboratory Beagles. Journal of Veterinary Pharmacology and Therapeutics; DOI: 10.1111/j.1365-2885.2010.01165.x.
7. Cusack, B.J. (2004) Pharmacokinetics in older persons. American Journal of Geriatric Pharmacotherapy, 2, 274-302.
8. EMEA (2008) European Medicines Agency, Trocoxil - European Public Assessment Report. Available at: Accessed 19 March 2010.
9. Hummel, B.D., Locuson, C.W., Benner, C.P., Zaya, M.J., Cox, T.D., Cox, S.R. & Stegemann, M.R. (2010) Manuscript in preparation.
10. Jonsson, E., Karlsson, M. & Milligan, P. (2007) Graphical displays for modeling population data. In Pharmacometrics: The Science of Quantitative Pharmacology. Eds Ette, E. & Williams, P., pp. 183-222. John Wiley and Sons, Hoboken, NJ.
11. Karlsson, M.O. & Savic, R.M. (2007) Diagnosing model diagnostics. Clinical Pharmacology & Therapeutics, 82, 17-20.
12. Krautmann, M.J., Boucher, J.F., Cox, S.R., Savides, M.C. & Stegemann, M.R. (2009) Target animal safety studies of mavacoxib in dogs. 11th International Congress of the European Association for Veterinary Pharmacology and Toxicology, Leipzig, Germany, Journal of Veterinary Pharmacology and Therapeutics, 32(Suppl. 1), 104-105.
13. Lees, P., Alexander-Bowman, S., Hummel, B., Kubiak, T., Michels, G., Krautmann, M., Cox, S., Toutain, P. & Stegemann, M. (2009) Pharmacokinetics and pharmacodynamics of mavacoxib in the dog. 11th International Congress of the European Association for Veterinary Pharmacology and Toxicology, Leipzig, Germany, 12-16 July. Journal of Veterinary Pharmacology and Therapeutics, 32(Suppl. 1), 105-106.
14. Lee Vee, M., Lecureur, V., Stieger, B. & Fardel, O. (2009) Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metabolism and Disposition, 37, 685-693.
15. Mangoni, A.A. (2007) The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. Expert Opinion on Drug Metabolism & Toxicology, 3, 315-320.
16. Parke, J., Holford, N.H. & Charles, B.G. (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Computer Methods and Programs in Biomedicine, 59, 19-29.
17. Payne-Johnson, M., Boucher, J.F. & Stegemann, M.R. (2009) Efficacy and safety of mavacoxib in the treatment of pain and inflammation associated with degenerative joint disease in dogs presented as veterinary patients. 11th Interational Congress of the European Association for Veterinary Pharmacology and Toxicology, Leipzig, Germany, 12-16 July. Journal of Veterinary Pharmacology and Therapeutics, 32(Suppl. 1), 106-107.
18. Renton, K.W. (2005) Regulation of drug metabolism and disposition during inflammation and infection. Expert Opinion on Drug Metabolism & Toxicology, 1, 629-640.
19. VICH (2000) International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products, Good Clinical Practice, June 2000 effective 1 July, VICH, Bruxelles, Belgium. Available at Accessed 19 March 2007.
20. Wauthier, V., Verbeeck, R.K. & Calderon, P.B. (2007) The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. Current Medicinal Chemistry, 14, 745-757.